# JSP191 Antibody Targeting Conditioning in SCID Patients

> **NCT02963064** · PHASE1,PHASE2 · TERMINATED · sponsor: **Jasper Therapeutics, Inc.** · enrollment: 23 (actual)

## Conditions studied

- SCID

## Interventions

- **BIOLOGICAL:** Humanized anti-CD117 Monoclonal Antibody (JSP191)

## Key facts

- **NCT ID:** NCT02963064
- **Lead sponsor:** Jasper Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-20
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963064, "JSP191 Antibody Targeting Conditioning in SCID Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02963064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*